Caring for patients with cholangiocarcinoma is deeply personal. Thank you @curecc for sharing my story! @UCLAHealth

Celebrating @Dodgers Manager and UCLA Jonsson Cancer Center Foundation Board Member Dave Roberts on guiding the @Dodgers to back-to-back World Championships! Your grit motivates our patients, staff and fans as you and Tricia Roberts help us in the fight against cancer.

We get it (I was just in your shoes). 9+ years of medical training, sometimes multiple degrees, 8 board exams, personal sacrifices, the list goes on and on. You want to and DESERVE to be happy with your first “real” job. I hope this data ease some fears!

A common concern last night: the job market. It’s becoming a tale as old as time…”the job market sucks!” Take a look at this years @ARRO_org survey data

Radiation dose in SBRT vs. Y90 in HCC. This confused me for the LONGEST time. Both measured in Gy, but clearly not the same – Y90 doses often reach 400Gy+, SBRT doses much lower (<50 Gy), yet both efficacious. Explained below. Bottom line is Y90 Gy ≠ SBRT Gy. @OncoAlert

📢 Calling all medical students! Join us for our next Med Student Q&A TODAY, Tuesday, Nov. 4, at 8 P.M. ET. This live session features a faculty RadOnc and a RadOnc resident, offering a unique opportunity to learn more about the specialty. @TrudyWuMD @IsaacLasko 🔗Reserve your

📢 Calling all medical students! Join us for our next Med Student Q&A on November 4, at 8 P.M. ET. This live session features a faculty RadOnc and a RadOnc resident, offering a unique opportunity to learn more about the specialty. @TrudyWuMD @IsaacLasko 🔗Reserve your spot:

Hi med students! Join us for this @ASTRO_org Q&A Webinar on Tuesday Nov 4th at 8 PM EST. Excited to meet and chat about our field! Register here: https://t.co/KlrNE9iQfI

Great to see the updated BCLC guidelines include RT! RT now incorporated into most major guidelines for HCC (BCLC, AASLD, EASL, NCCN, others) & should be a standard of care option. Full link here: https://t.co/EagzIPdmVL @OncoAlert

Too many mediocre men talk over capable women. Study of problem-solving teams: Men dominate the conversation, taking 50% more turns and saying 69% more than women. Men with low skill speak more than women with high skill. It's long past time to value competence over confidence.

⏰ 1 WEEK LEFT! Submit your abstract for the ARS 108th Annual Meeting by Nov 1, 2025 (11:59 PM EST). Join us in Newport Beach, CA, April 30–May 3, 2026! https://t.co/0rYcNq9qnl

How to pack for a professional conference All this using only 1 carry-on + 1 personal item, no checked luggage 🙂 Work with @TrudyWuMD

How cool is this?! Our @ASTRO_org president and Radiation Oncologist @NehaVapiwala featured on @people! What a role model!

Congratulations to President @JoeBiden for finishing RT under the care of @ASTRO_org President @NehaVapiwala @PennMedicine #radonc

💚 October is Liver Cancer Awareness Month. Cholangiocarcinoma (bile duct cancer) is a rare and complex form of liver cancer — but awareness can lead to earlier diagnosis and better outcomes. Swipe ➡️ to learn about risk factors, symptoms, and how the Cholangiocarcinoma

PREOPANC-2 drops… and it’s a draw 🤜🤛 #ESMO25 Phase 3 trial out of the Netherlands comparing neoadjuvant FOLFIRINOX vs gemcitabine-based chemoradiotherapy (Gem-CRT) for resectable and borderline resectable pancreatic cancer. 🎯 Median OS: 21.9 mo (FOLFIRINOX) vs 21.3 mo

Holy smokes, MATTERHORN hits OS! 🏔️🔥 We’ve been waiting for this one. After FLOT became standard for resectable gastric and GEJ adenocarcinoma, everyone wondered if adding immunotherapy could move the bar. Earlier this year, MATTERHORN showed a big EFS win for DFLOT, along with

Hepatic Arterial Infusion Pump Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma 🔎PUMP-2 Trial @JCO_ASCO https://t.co/EMwfTeeo8Z 👉48 pts HAIP floxuridine + CTx 👉PR: 44%; DCR: 84% 👉1-year OS: 80.0% 🧐strong signal, interesting opportunity for downstaging,

In RAPIDO, higher LRR w short course TNT confined to pts undergoing sphincter-preserving surg (12 v 5%), w distal resection margin <1cm as predictor. Suggests need to re-eval safe margin & consider basing surg off original tumor extent. Caveat: post hoc, exploratory analysis.

For over a year, our department at @UCLAHealth has been offering same-day consults because no cancer patient should have to wait to meet with a radiation oncologist @MSteinbergMD @AmarUKishan @UCLAHealthJCCC

My first #ASTRO as @UCLA faculty. What an enjoyable time with my rad onc family! Leaving the Bay inspired and optimistic for the future of cancer care